Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients with Head and Neck Cancer: Results of the Biology-Driven Phase Ii Clinical Trial Pravacur
Previous preclinical investigations based on the inhibition of the Rho/ROCK/CTGF pathway brought the biological rationale for this bicentric phase II clinical trial on the use of statins for the treatment of established radio-induced fibrosis. This trial showed that pravastatin (40mg/day for 12 months) is a safe and efficient anti-fibrotic agent in patients with established grade ≥2 cutaneous and subcutaneous fibrosis after head and neck cancer radiotherapy. These results support the concept of fibrosis reversibility.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Celine Bourgier, Anne Auperin, Sofia Rivera, Pierre Boisselier, Benoit Petit, Philippe Lang, Nathalie Lassau, Patrice Taourel, Raphael Tetreau, David Azria, Jean Bourhis, Eric Deutsch, Marie-Catherine Vozenin Tags: Clinical Investigation Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Cholesterol | Clinical Trials | Head and Neck Cancer | Physics | Pravastatin | Radiology | Statin Therapy